Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Vitiligo: early-phase trial registry

3 of 16 indexed Vitiligo trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,060 of 28,707 conditions by registered trial count.

16 US clinical trials · 3 currently recruiting · #1,060 of 28,707 conditions by registered trial count

Vitiligo: 16 US clinical trials tracked, 3 recruiting.

Vitiligo is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Medical University of South Carolina, running 2 of these trials.

Enrollment posture brief

Registry condition vitiligo

OPEN 3 | RECR 19% | LATE 3 | EARLY 8 | RANK #1060 | SPON 2

Nearest open-share peer: Bacterial Vaginosis (19% recruiting · 16 trials)

Adolescent62.5%Alcohol Intoxication56.3%AL Amyloidosis43.8%Vitiligo (this)19%Allergy18.8%
Open-enrollment share among volume-matched conditions near Vitiligo

Vitiligo lists 3 open slots (19% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Vitiligo on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Vitiligo is recruiting below its size-band peers.

    3 of 16 indexed trials (18.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Vitiligo trials is spread across many organizations.

    Medical University of South Carolina accounts for 2 of 16 trials (12.5%). 15 distinct sponsors appear on at least one study for this condition label.

  3. Typical Vitiligo enrolment sits around 80 participants.

    Median target enrolment is 80 among the 16 trials that report a genuine target (sentinel values excluded). 9 of those (56.3%) plan for fewer than 100 participants.

  4. Vitiligo research is mostly interventional.

    14 interventional and 2 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 25Phase 33

Open and recent trials

16 total, page 1 of 1

RECRUITING Phase 3 400 participants

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

Pfizer

NCT06163326

RECRUITING 100 participants

The Gut and Skin Microbiome in Vitiligo Disease Progression

Northwestern University

NCT03577327

RECRUITING Phase 1 80 participants

A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo

Dren Bio

NCT06602232

ACTIVE NOT RECRUITING 15,000 participants

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Target PharmaSolutions

NCT03661866

ACTIVE NOT RECRUITING Phase 3 614 participants

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

AbbVie

NCT06118411

ACTIVE NOT RECRUITING Phase 3 200 participants

A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

Clinuvel

NCT06109649

ACTIVE NOT RECRUITING Phase 1 38 participants

A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo

Teva Branded Pharmaceutical Products R&D

NCT06625177

ACTIVE NOT RECRUITING Phase 2 20 participants

Daily Topical Rapamycin for Vitiligo

Medical University of South Carolina

NCT05342519

COMPLETED Phase 2 157 participants

A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo

Incyte Corporation

NCT03099304

COMPLETED NA 109 participants

Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells

Avita Medical

NCT05971381

COMPLETED Phase 2 60 participants

Evaluation of AMG 714 for Vitiligo

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04338581

COMPLETED Phase 2 34 participants

A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo

Aclaris Therapeutics

NCT03468855

COMPLETED Phase 2 23 participants

Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo

Icahn School of Medicine at Mount Sinai

NCT03123016

COMPLETED NA 15 participants

Photocil (Topical) for the Treatment of Vitiligo

Applied Biology

NCT01992185

COMPLETED NA 10 participants

Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy

Johns Hopkins University

NCT03270241

COMPLETED Early Phase 1 4 participants

Effect of Microneedling, Bimatoprost and Excimer in Vitiligo Treatment

Medical University of South Carolina

NCT04738149

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 5
Phase 3 3

Named interventions

Most-linked intervention names on Vitiligo records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
3 trials
RECELL® Autologous Cell Harvesting Device Device
1 trials
Microneedling with a dermaroller Device
1 trials
Excimer laser Device
1 trials
ATI-50002 topical solution Drug
1 trials
nbUVB phototherapy Procedure
1 trials
AMG 714 Biological
1 trials
NB-UVB phototherapy Procedure
1 trials

US sites by state

Facility locations filed on Vitiligo trials. A trial with sites in several states counts in each.

California 10 trials
Florida 8 trials
Michigan 7 trials
New York 6 trials
Massachusetts 6 trials
Illinois 5 trials
Arizona 5 trials
Texas 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Vitiligo page

16 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Vitiligo condition card totals 16 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.